Brave Asset Management’s Medicus Pharma MDCX Stock Holding History

Brave Asset Management’s Portfolio MDCX Stock Details MDCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,000	Closed	-$4.56K	–	173
2026 Q1	$4.56K	Sell	10,000 -10,000	-50%	-$10.4K	﹤0.01%	159
2025 Q4	$30.6K	Hold	20,000	–	–	0.01%	160
2025 Q3	$46.3K	Buy	+20,000	New	+$50.2K	0.01%	163

Other funds holding MDCX

ICP

Interchange Capital Partners Pittsburgh, Pennsylvania $532M AUM 26.57% 1-Year Est. Return

SIAP

Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

WSFS

Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return

MCM

Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return

Brave Asset Management's MDCX Position: Q2 2026 in Review

Brave Asset Management sold out of Medicus Pharma (MDCX) in Q2 2026, closing a stake of 10,000 shares — an estimated $4.56K sold.

Brave Asset Management first reported a position in MDCX in Q3 2025 and held it in 3 quarters. The position peaked at $46.3K in Q3 2025. 6 funds tracked by Wall St. Rank hold MDCX as of Q2 2026.

Brave Asset Management reported no remaining Medicus Pharma position as of Q2 2026 after selling out during the quarter.
Brave Asset Management sold 10,000 Medicus Pharma shares in Q2 2026, an estimated $4.56K.
Brave Asset Management first reported a position in Medicus Pharma in Q3 2025 and held it in 3 quarters.
Brave Asset Management's Medicus Pharma position peaked at $46.3K in Q3 2025.
6 funds tracked by Wall St. Rank held Medicus Pharma as of Q2 2026.

Based on Brave Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.